Multivariate analysis in the entire cohort
| . | RR of NRM (95% confidence interval) . | P . | RR of death (95% confidence interval) . | P . |
|---|---|---|---|---|
| HCT-CI | ||||
| 0* | 1.0 | 1.0 | ||
| 1-2 | 1.5 (0.6-4.0) | .48 | 2.6 (1.2-5.6) | .01† |
| ≥ 3 | 4.5 (1.7-12.1) | < .01† | 4.6 (2.1-9.7) | < .01† |
| Age, y | ||||
| 0-1* | 1.0 | 1.0 | ||
| 2-10 | 0.5 (0.2-1.3) | .14 | 0.6 (0.3-1.3) | .24 |
| 11-20 | 0.5 (0.2-1.4) | .18 | 0.8 (0.4-1.7) | .52 |
| Conditioning | ||||
| RIC/NMA* | 1.0 | 1.0 | ||
| MA | 2.8 (0.9-8.4) | .07 | 2.3 (1.0-5.4) | .06 |
| Center | ||||
| CCHMC* | 1.0 | 1.0 | ||
| DFCI/CHB | 0.6 (0.2-3.1) | .37 | 1.6 (0.6-4.0) | .32 |
| UMACH | 0.8 (0.2-3.1) | .78 | 1.4 (0.5-3.9) | .48 |
| TXCCC | 1.0 (0.3-3.6) | .98 | 1.4 (0.5-3.6) | .55 |
| . | RR of NRM (95% confidence interval) . | P . | RR of death (95% confidence interval) . | P . |
|---|---|---|---|---|
| HCT-CI | ||||
| 0* | 1.0 | 1.0 | ||
| 1-2 | 1.5 (0.6-4.0) | .48 | 2.6 (1.2-5.6) | .01† |
| ≥ 3 | 4.5 (1.7-12.1) | < .01† | 4.6 (2.1-9.7) | < .01† |
| Age, y | ||||
| 0-1* | 1.0 | 1.0 | ||
| 2-10 | 0.5 (0.2-1.3) | .14 | 0.6 (0.3-1.3) | .24 |
| 11-20 | 0.5 (0.2-1.4) | .18 | 0.8 (0.4-1.7) | .52 |
| Conditioning | ||||
| RIC/NMA* | 1.0 | 1.0 | ||
| MA | 2.8 (0.9-8.4) | .07 | 2.3 (1.0-5.4) | .06 |
| Center | ||||
| CCHMC* | 1.0 | 1.0 | ||
| DFCI/CHB | 0.6 (0.2-3.1) | .37 | 1.6 (0.6-4.0) | .32 |
| UMACH | 0.8 (0.2-3.1) | .78 | 1.4 (0.5-3.9) | .48 |
| TXCCC | 1.0 (0.3-3.6) | .98 | 1.4 (0.5-3.6) | .55 |
CCHMC indicates Cincinnati Children's Hospital Medical Center; DFCI/CHB, Dana-Farber Cancer Institute/Children's Hospital Boston; UMACH, University of Minnesota Amplatz Children's Hospital; TXCCC, Texas Children's Cancer Center; RR, relative risk; NRM, nonrelapse mortality; RIC, reduced-intensity conditioning; NMA, nonmyeloablative; and MA, myeloablative.
Reference group.